Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors in Telix Pharmaceuticals Ltd. for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements regarding the company's business and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Telix's defendants made materially false and misleading statements about the progress of prostate cancer therapeutic candidates and the quality of the company's supply chain and partners [5]. - Investors who purchased Telix securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].